Adherex Technologies Inc. (NASDAQ:FENC – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $15.40.
Several analysts have issued reports on FENC shares. HC Wainwright upped their price target on shares of Adherex Technologies from $13.00 to $16.00 and gave the company a “buy” rating in a report on Friday, May 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Adherex Technologies in a research report on Tuesday, April 21st. Wall Street Zen raised Adherex Technologies from a “hold” rating to a “strong-buy” rating in a research note on Saturday, May 16th. Zacks Research raised Adherex Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. Finally, Wedbush reiterated an “outperform” rating and set a $13.00 target price on shares of Adherex Technologies in a report on Thursday, April 16th.
Check Out Our Latest Stock Report on FENC
Insider Activity at Adherex Technologies
Institutional Inflows and Outflows
A hedge fund recently bought a new position in Adherex Technologies stock. Jane Street Group LLC bought a new stake in Adherex Technologies Inc. (NASDAQ:FENC – Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 14,718 shares of the company’s stock, valued at approximately $90,000. Jane Street Group LLC owned approximately 0.05% of Adherex Technologies at the end of the most recent quarter. Institutional investors own 55.51% of the company’s stock.
Adherex Technologies Stock Performance
Adherex Technologies stock opened at $10.44 on Friday. Adherex Technologies has a fifty-two week low of $5.65 and a fifty-two week high of $11.31. The stock’s fifty day moving average is $9.65 and its two-hundred day moving average is $8.19. The firm has a market capitalization of $364.25 million, a price-to-earnings ratio of -36.00 and a beta of 1.07.
Adherex Technologies (NASDAQ:FENC – Get Free Report) last posted its earnings results on Thursday, May 14th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. The firm had revenue of $15.11 million during the quarter, compared to the consensus estimate of $13.90 million. Adherex Technologies had a negative net margin of 17.12% and a negative return on equity of 43.87%. As a group, sell-side analysts forecast that Adherex Technologies will post 0.26 EPS for the current fiscal year.
Adherex Technologies Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.
Featured Articles
- Five stocks we like better than Adherex Technologies
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
